gastroparesis glp 1 agonist Diabetic glp-1_analogs [TUSOM | Pharmwiki]

hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)

Ozempic has become a buzzword in weight loss and type 2 diabetes management

Limitations The major limitations of the studies that are included in this systematic review are the enrollment of healthy subjects and insufficient data in conditions that might affect pharmacokinetics (e.g., kidney dysfunction)

Upper respiratory tract infections (URTIs) were the most frequently reported adverse event (8 of 12 reporting studies, 66.7%), occurring at rates comparable to controls across RCTs (GRADE: MODERATE certainty)

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases

Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios